
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
Argenx has demonstrated significant growth in revenue, with $790 million reported in Q1 2025 and $949 million in Q2 2025, reflecting robust year-over-year increases driven by broadened uptake of Vyvgart in treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The introduction of the pre-filled syringe (PFS) format has notably expanded the prescriber base, with around 1,000 PFS prescribers identified, including 150 new prescribers, indicating strong potential for market penetration. In addition, the positive clinical outcomes from studies, particularly in functional improvements noted in the 6-Minute Walk Test, further bolster confidence in the company's innovative pipeline addressing rare autoimmune diseases.
Bears say
Argenx faces significant risks that could adversely impact its financial performance, primarily due to lower-than-expected growth in sales of its lead product, Vyvgart, and potential safety concerns arising from ongoing trials of its therapies. Additionally, the company must contend with the emergence of new competitors and various macroeconomic factors, including foreign exchange fluctuations, inflation, and shipping risks, which may further detract from its revenue forecasts. Ultimately, any R&D, regulatory, or commercial setbacks could undermine investor confidence and negatively affect Argenx's market position and stock performance.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares